Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

VRDN Relative to the S&P 500

VRDN Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Viridian Therapeutics, Inc. (NASD:VRDN) seasonal charts above shows that a Buy Date of November 8 and a Sell Date of February 2 has resulted in a geometric average return of 17.12% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 49.24% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

To download VRDN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: VRDN